Advanced Filters
noise

Carcinoma Clinical Trials

A listing of Carcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 6,163 clinical trials

PT-112 in Subjects With Thymoma and Thymic Carcinoma

Background There are no approved drugs to treat recurrent thymoma and thymic carcinoma. New therapies are needed for people with these cancers. Researchers want to see if the drug PT-112 can help. PT-112 kills cancer cells. It also helps the body s immune system fight cancer. Objective To see if …

18 - 120 years of age All Phase 2
P Principal Investigator Selected by Sponsor, M.D., Ph.D.

Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)

The peculiarity of anal cancers, with well-established radical chemoradiotherapy that allows tumor-neoantigen formation with platinum-based chemotherapy and radiotherapy with radio-sensitizing chemotherapy could create the perfect environment for immunotherapy in this setting, not only to increase the probability of pathological complete response (CCR) but also creating neoantigen exposure and immune-prevention to …

18 years of age All Phase 2
L Lydia Giles, BSN, RN

Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma

The main purpose of this study is to determine the response of Merkel cell carcinoma to pembrolizumab before surgery and to determine whether it further reduces the risk for disease recurrence. Another purpose of this study is to look at the side effects that occur when the experimental drug pembrolizumab …

18 years of age All Phase 2
B Birgitta Lindh, MD

Proton Versus Photon Therapy in Anal Squamous Cell Carcinoma

Dosimetric studies suggest that radiotherapy with protons has a potential to reduce side effects compared to treatment with photons for patients with anal carcinoma (AC). There are so far no studies comparing these treatment techniques in a randomised setting. The aim of this study is to compare side effects following …

18 years of age All Phase N/A
H Hasmik Ghazinian, MD

Establishment of a Tissue Registry for Hepatocellular Carcinoma Specimens

The goal of the study is to establish a cancer registry to facilitate research and assist in the identification of additional risk factors for hepatocellular carcinoma. The main objectives are: provide a mechanism to store the information about subjects with hepatocellular carcinoma use of tissue samples for translational/further research purposes

years of age All Phase N/A
M Marek Ruchała, Prof.

Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.

This study is a national, multicenter, interventional, phase II clinical trial on the use of pembrolizumab in advanced adrenocortical carcinoma, with confirmed progression within 6 months, following EDP or EDP-M ( etoposide, doxorubicin, cisplatin- mitotan) chemotherapy. Adrenocortical carcinoma is a very rare entity with poor prognosis and limited therapeutic options. …

18 years of age All Phase 2

GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma

This study is to evaluate whether intraoperative fluorescence imaging targeting GPC3 can aid improve the surgical accuracy of hepatocellular carcinoma. The main purposes of this study include: ① To raise the detection rate of hepatocellular carcinoma intraoperatively using the novel NIR-II fluorescence molecular imaging and the GPC-3 targeted fluorophore. ② …

18 - 75 years of age All Phase N/A
C Costantino Errani, MD, PhD

Fracture Risk Evaluation of Bone Metastases Derived From Carcinoma

From the archives of the Rizzoli institute all patients (approximately 750) treated for bone metastases from 01/01/2010 to 31/12/2022. A review will be made from the medical records, radiological imaging, and histological data of these patients

18 years of age All Phase N/A
G Guohui Xu

TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most common cause of cancer-related death worldwide. The majority of patients with HCC are diagnosed as intermediate or advanced stage disease, and not eligible for curative treatments including transplantation, resection, and ablation. Transarterial chemoembolization (TACE) is recommended as …

18 - 80 years of age All Phase 3
H Haibo Sun

Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma

No adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemotherapy plus surgery and incidental pathologic lymph node metastasis following initial surgery for esophageal squamous cell carcinoma (ESCC).Controversy still exists regarding the role of adjuvant immunotherapy for ESCC patients who do not achieve …

18 - 70 years of age All Phase 3

Simplify language using AI